(Rac) -Zevaquenabant
(Rac) -Zevaquenabant ((Rac) -MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R) /iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac) -Zevaquenabant is potential for the research of liver fibrosis[1].
Product Specifications
CAS Number
[1610420-28-4]
Product Name Alternative
(Rac) -MRI-1867
UNSPSC
12352005
Target
Cannabinoid Receptor; NO Synthase
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/rac-zevaquenabant.html
Purity
99.20
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=S(/N=C(N1N=C(C2=CC=C(Cl)C=C2)C(C3=CC=CC=C3)C1)/N=C(N)/C)(C4=CC=C(C(F)(F)F)C=C4)=O
Molecular Formula
C25H21ClF3N5O2S
Molecular Weight
547.98
References & Citations
[1]Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB 1 R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
INOS
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
